William Blair analyst Lachlan Hanbury Brown maintained a Hold rating on Lyra Therapeutics today. The company’s shares opened today at $7.47.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Hanbury Brown is a 5-star analyst with an average return of 38.6% and a 75.00% success rate. Hanbury Brown covers the Healthcare sector, focusing on stocks such as ARS Pharmaceuticals, Harrow Health, and Ocular Therapeutix.
Currently, the analyst consensus on Lyra Therapeutics is a Hold with an average price target of $16.00.
LYRA market cap is currently $11.51M and has a P/E ratio of -0.24.
Read More on LYRA:
Disclaimer & DisclosureReport an Issue
- Lyra Therapeutics announces clinical plan for LYR-210
- Lyra Therapeutics Posts Corporate Presentation on LYR-210
- Lyra Therapeutics Receives Nasdaq Deficiency Letter
- Cautious Hold Rating on Lyra Therapeutics Amid Uncertainty in LYR-210’s Development and Approval Prospects
- Lyra Therapeutics Faces Manufacturing and Staffing Challenges Amid LYR-210 Production Shift